The FDA outlined proposals in its 2027 budget to encourage domestic drug development and manufacturing, including a plan to make it easier for companies to start early clinical testing in the U.S. The agency also described an “exclusivity” period concept for U.S.-based generics manufacturers. The proposal was framed as a response to international competition, particularly China’s influence on early-stage development activity, and aims to reduce development friction and costs for sponsors evaluating U.S. trial sites. Industry stakeholders are expected to scrutinize how proposals would be implemented, including whether they require legislative change. If adopted, the FDA’s approach could alter the near-term calculus for sponsors deciding where to run first-in-human studies and how to structure early development timelines.